Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
McKesson
Fuji
Chinese Patent Office
Cantor Fitzgerald
US Army
Julphar
Cerilliant
Federal Trade Commission

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,713,485

« Back to Dashboard

Which drugs does patent 6,713,485 protect, and when does it expire?

Patent 6,713,485 protects TYKERB and is included in one NDA.

This patent has seventy patent family members in forty-six countries.
Summary for Patent: 6,713,485
Title: Heterocyclic compounds
Abstract:The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.
Inventor(s): Carter; Malcolm Clive (Ware, GB), Cockerill; George Stuart (Bedford, GB), Guntrip; Stephen Barry (Hertford, GB), Lackey; Karen Elizabeth (Hillsborough, NC), Smith; Kathryn Jane (Hertfordshire, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/071,358
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

Drugs Protected by US Patent 6,713,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB ➤ Sign Up
Novartis Pharms Corp TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,713,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9800569Jan 12, 1998
PCT/EP99/00048Jan 08, 1999

Non-Orange Book US Patents Family Members for Patent 6,713,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,727,256 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Sign Up
8,912,205 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Sign Up
9,199,973 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Sign Up
7,109,333 Heterocyclic compounds ➤ Sign Up
8,513,262 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,713,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2317589 ➤ Sign Up
China 1292788 ➤ Sign Up
China 1134438 ➤ Sign Up
Colombia 4820390 ➤ Sign Up
Cyprus 1108859 ➤ Sign Up
Czech Republic 20002587 ➤ Sign Up
African Regional IP Organization (ARIPO) 1446 ➤ Sign Up
Czech Republic 298047 ➤ Sign Up
Germany 69918528 ➤ Sign Up
Germany 69930773 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
AstraZeneca
Fish and Richardson
Johnson and Johnson
Chinese Patent Office
Mallinckrodt
Julphar
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot